Related Experiment Video

Updated: Sep 10, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.1K

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis

Luis Garegnani1, Camila Micaela Escobar Liquitay1, Ignacio Esteban2,3

  • 1Associate Cochrane Centre, Universidad Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

The Cochrane Database of Systematic Reviews
|August 20, 2025
PubMed

Insights

This review compares monoclonal antibodies (mAbs) to prevent respiratory syncytial virus (RSV) in children. It ranks the benefits and harms of these important interventions for pediatric RSV prevention.

Area of Science:

  • Pediatric infectious diseases
  • Immunology
  • Public health

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and young children.
  • Monoclonal antibodies (mAbs) are available for RSV prophylaxis, but their comparative effectiveness and safety profiles require evaluation.
  • Understanding the benefits and harms of different mAbs is crucial for optimizing pediatric RSV prevention strategies.

Purpose of the Study:

  • To assess the comparative effectiveness of different monoclonal antibodies (mAbs) in preventing respiratory syncytial virus (RSV) infection in children.
  • To evaluate the relative rankings of benefits and harms associated with mAbs used for pediatric RSV prevention.
  • To provide evidence-based guidance for clinicians and policymakers regarding the use of mAbs for RSV prophylaxis in children.

Main Methods:

  • This is a protocol for a Cochrane Review, indicating a systematic approach to evidence synthesis.
  • The review will compare the effectiveness of various monoclonal antibodies (mAbs) for preventing RSV infection.
  • The evaluation will include a comprehensive assessment of both the benefits and harms of these interventions.

Main Results:

  • The review aims to identify which monoclonal antibodies (mAbs) offer the greatest protection against RSV in children.
  • It will systematically compare the adverse events and overall safety profiles of different mAbs.
  • The findings will facilitate a clear ranking of mAbs based on their risk-benefit ratio for pediatric RSV prevention.

Conclusions:

  • This Cochrane Review protocol outlines a rigorous plan to compare the effectiveness and safety of monoclonal antibodies (mAbs) for preventing RSV in children.
  • The anticipated results will inform clinical decision-making and public health policies for pediatric RSV prevention.
  • A clear understanding of the comparative benefits and harms of mAbs is essential for optimizing child health outcomes related to RSV.
Abstract

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.1K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.0K

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
463
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
358
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
909
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
456